Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $3.33

Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) have received an average rating of “Moderate Buy” from the eight analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $3.3333.

A number of research analysts have recently commented on the company. D. Boral Capital reiterated a “buy” rating and issued a $2.00 price target on shares of Reviva Pharmaceuticals in a research note on Tuesday, December 23rd. Wall Street Zen upgraded Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 27th. Chardan Capital reaffirmed a “buy” rating and issued a $2.00 price objective on shares of Reviva Pharmaceuticals in a research note on Monday, January 5th. HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday, December 23rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Thursday, January 22nd.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new stake in shares of Reviva Pharmaceuticals in the second quarter valued at about $31,000. Lido Advisors LLC bought a new stake in Reviva Pharmaceuticals in the third quarter valued at approximately $37,000. NewEdge Advisors LLC acquired a new stake in Reviva Pharmaceuticals during the 1st quarter valued at approximately $58,000. State Street Corp increased its position in Reviva Pharmaceuticals by 202.4% during the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after purchasing an additional 256,500 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Reviva Pharmaceuticals by 6.9% during the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after purchasing an additional 29,063 shares during the last quarter. 63.18% of the stock is owned by institutional investors and hedge funds.

Reviva Pharmaceuticals Price Performance

RVPH stock opened at $0.26 on Friday. The company has a 50 day simple moving average of $0.36 and a 200 day simple moving average of $0.46. The stock has a market cap of $30.41 million, a price-to-earnings ratio of -0.57 and a beta of 0.06. Reviva Pharmaceuticals has a 1 year low of $0.25 and a 1 year high of $1.88.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.